QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Sharma, S. V. Articles by Settleman, J. PubMed PubMed Citation Articles by Sharma, S. V. Articles by Settleman, J. Related Content Cancer and Disease Models Social Bookmarking                   What's this?

REVIEW

Oncogene addiction: setting the stage for molecularly targeted cancer therapy

Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA

In pugilistic parlance, the one-two punch is a devastating combination of blows, with the first punch setting the stage and the second delivering the knock-out. This analogy can be extended to molecularly targeted cancer therapies, with oncogene addiction serving to set the stage for tumor cell killing by a targeted therapeutic agent. While in vitro and in vivo examples abound documenting the existence of this phenomenon, the mechanistic underpinnings that govern oncogene addiction are just beginning to emerge. Our current inability to fully exploit this weakness of cancer cells stems from an incomplete understanding of oncogene addiction, which nonetheless represents one of the rare chinks in the formidable armor of cancer cells.

[Keywords: Oncogene addiction; cancer; targeted therapy; signal transduction]]

E-MAIL settleman{at}helix.mgh.harvard.edu; FAX (617) 726-7808.

Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.1609907

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?